RxPONDER: What the Breast Cancer Trial Found

A trial designed to take treatment away

Most cancer trials ask whether adding something helps. RxPONDER asked the opposite question: which women with node-positive breast cancer can safely skip chemotherapy?

It was a phase 3 randomized trial, registered as NCT01272037, funded by the National Cancer Institute and others. The results were published in the New England Journal of Medicine in December 2021.

What the 21-gene recurrence score is

After breast cancer surgery, a sample of the tumor can be sent for a test that measures the activity of 21 genes. The result is a recurrence score from 0 to 100, where higher means a worse prognosis.

The score had already been shown to help predict who benefits from chemotherapy in breast cancer that had not reached the lymph nodes. Whether it worked the same way once cancer had reached the nodes was unclear. That gap is what RxPONDER set out to close.

Our page on biomarker testing explains how tests like this differ from the routine pathology done on every tumor.

Who took part

The trial enrolled women with hormone receptor-positive, HER2-negative breast cancer, one to three positive lymph nodes under the arm, and a recurrence score of 25 or lower.

A total of 5,083 women underwent randomization and 5,018 took part. Of those, 33.2 percent were premenopausal and 66.8 percent were postmenopausal. Half were assigned to endocrine therapy alone, meaning hormone-blocking drugs, and half to chemotherapy followed by endocrine therapy.

The main measure was invasive disease-free survival: time without the cancer coming back as invasive disease, without a new cancer, and without death from any cause.

The answer split down the middle

At a pre-planned interim analysis, the effect of chemotherapy differed by menopausal status, and the two groups were then analyzed separately.

Among postmenopausal women, five-year invasive disease-free survival was 91.9 percent with endocrine therapy alone and 91.3 percent with chemotherapy added. The hazard ratio was 1.02, with a 95 percent confidence interval of 0.82 to 1.26 and a p-value of 0.89. In plain terms: chemotherapy added nothing measurable.

Among premenopausal women, the same measure was 89.0 percent with endocrine therapy alone and 93.9 percent with chemotherapy added. The hazard ratio was 0.60, confidence interval 0.43 to 0.83, p-value 0.002. That is an absolute difference of 4.9 percentage points at five years. Distant relapse-free survival moved in the same direction, hazard ratio 0.58, confidence interval 0.39 to 0.87, p-value 0.009.

One further finding is easy to miss and matters: within this range of scores, the relative benefit of chemotherapy did not increase as the recurrence score rose.

Why "sparing chemotherapy" is a clinical result

Chemotherapy is not neutral. It brings hair loss, nausea, infection risk from low blood counts, fatigue, and for some people lasting nerve damage or effects on the heart or fertility. Our overview of chemotherapy and our page on side effects set out what that involves.

For most postmenopausal women in this trial, all of that carried no measurable gain. Finding that out is as useful as finding a new drug, and it is far rarer, because trials that remove treatment are harder to fund and harder to run.

The unresolved question about premenopausal women

Chemotherapy does not only kill cancer cells. In premenopausal women it often damages the ovaries and shuts down estrogen production, sometimes permanently.

Since this cancer is driven by estrogen, some or all of the benefit seen in premenopausal women could come from that shutdown rather than from a direct effect on the cancer. RxPONDER was not designed to separate the two, and it cannot. This is an active debate, and it has practical consequences, because ovarian suppression can be achieved with drugs instead.

Where breast cancer sits statistically

The American Cancer Society expects 321,910 new female breast cancers in the United States in 2026 and 42,140 deaths, and SEER, the federal cancer statistics program, republishes those. SEER's own staging data show about 27 percent are found after the cancer has reached nearby lymph nodes, which is the setting RxPONDER studied.

Five-year relative survival across all stages was 91.9 percent for women diagnosed from 2016 through 2022, and death rates are falling. That is a group statistic describing women diagnosed years ago. It is not a forecast for anyone.

What this trial cannot tell you

• It applies only to recurrence scores of 25 or lower. Women with higher scores were not randomized, so the trial says nothing about them.
• It cannot separate a direct anti-cancer effect of chemotherapy in premenopausal women from the effect of chemotherapy-induced ovarian shutdown.
• The reported results are at five years. That is early for hormone receptor-positive breast cancer, where recurrences continue for well over a decade.
• Entry criteria were specific: one to three positive nodes, hormone receptor-positive, HER2-negative. Someone outside those bounds is outside the finding.
• A trial result is an input to a conversation, not an instruction. Our page on clinical trials versus standard treatment covers how those two fit together.

Sources

• https://pubmed.ncbi.nlm.nih.gov/34914339/
• https://clinicaltrials.gov/api/v2/studies/NCT01272037
• https://www.cancer.gov/types/breast
• https://seer.cancer.gov/statfacts/html/breast.html

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

See an error, old source, or unclear wording? Tell us.